These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15833583)

  • 1. Fluoxetine in adolescents with comorbid major depression and an alcohol use disorder: a 3-year follow-up study.
    Cornelius JR; Clark DB; Bukstein OG; Kelly TM; Salloum IM; Wood DS
    Addict Behav; 2005 May; 30(4):807-14. PubMed ID: 15833583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoxetine in depressed AUD adolescents: a 1-year follow-up evaluation.
    Cornelius JR; Bukstein OG; Salloum IM; Kelly TM; Wood DS; Clark DB
    J Child Adolesc Psychopharmacol; 2004; 14(1):33-8. PubMed ID: 15142389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder.
    Cornelius JR; Bukstein OG; Wood DS; Kirisci L; Douaihy A; Clark DB
    Addict Behav; 2009 Oct; 34(10):905-9. PubMed ID: 19321268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a treatment trial of comorbid MDD/AUD adolescents.
    Cornelius JR; Douaihy A; Bukstein OG; Daley DC; Wood SD; Kelly TM; Salloum IM
    Addict Behav; 2011 Aug; 36(8):843-8. PubMed ID: 21530092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluoxetine in adolescents with major depression and an alcohol use disorder: an open-label trial.
    Cornelius JR; Bukstein OG; Birmaher B; Salloum IM; Lynch K; Pollock NK; Gershon S; Clark D
    Addict Behav; 2001; 26(5):735-9. PubMed ID: 11676382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review.
    Cornelius JR; Clark DB; Bukstein OG; Birmaher B; Salloum IM; Brown SA
    Addict Behav; 2005 Oct; 30(9):1824-33. PubMed ID: 16102905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.
    Goodyer IM; Dubicka B; Wilkinson P; Kelvin R; Roberts C; Byford S; Breen S; Ford C; Barrett B; Leech A; Rothwell J; White L; Harrington R
    Health Technol Assess; 2008 May; 12(14):iii-iv, ix-60. PubMed ID: 18462573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial.
    Davey CG; Chanen AM; Hetrick SE; Cotton SM; Ratheesh A; Amminger GP; Koutsogiannis J; Phelan M; Mullen E; Harrison BJ; Rice S; Parker AG; Dean OM; Weller A; Kerr M; Quinn AL; Catania L; Kazantzis N; McGorry PD; Berk M
    Lancet Psychiatry; 2019 Sep; 6(9):735-744. PubMed ID: 31371212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study.
    Kendrick T; Chatwin J; Dowrick C; Tylee A; Morriss R; Peveler R; Leese M; McCrone P; Harris T; Moore M; Byng R; Brown G; Barthel S; Mander H; Ring A; Kelly V; Wallace V; Gabbay M; Craig T; Mann A
    Health Technol Assess; 2009 Apr; 13(22):iii-iv, ix-xi, 1-159. PubMed ID: 19401066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TREATMENT TRIAL AND LONG-TERM FOLLOW-UP EVALUATION AMONG COMORBID YOUTH WITH MAJOR DEPRESSION AND A CANNABIS USE DISORDER.
    Cornelius JR; Salloum IM; Ferrell R; Douaihy AB; Hayes J; Kirisci L; Horner M; Daley DC
    Int J Med Biol Front; 2012; 18(6):399-411. PubMed ID: 25328373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.
    Cornelius JR; Bukstein OG; Douaihy AB; Clark DB; Chung TA; Daley DC; Wood DS; Brown SJ
    Drug Alcohol Depend; 2010 Nov; 112(1-2):39-45. PubMed ID: 20576364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continued Effectiveness of Relapse Prevention Cognitive-Behavioral Therapy Following Fluoxetine Treatment in Youth With Major Depressive Disorder.
    Emslie GJ; Kennard BD; Mayes TL; Nakonezny PA; Moore J; Jones JM; Foxwell AA; King J
    J Am Acad Child Adolesc Psychiatry; 2015 Dec; 54(12):991-8. PubMed ID: 26598474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substance use and the treatment of resistant depression in adolescents.
    Goldstein BI; Shamseddeen W; Spirito A; Emslie G; Clarke G; Wagner KD; Asarnow JR; Vitiello B; Ryan N; Birmaher B; Mayes T; Onorato M; Zelazny J; Brent DA
    J Am Acad Child Adolesc Psychiatry; 2009 Dec; 48(12):1182-92. PubMed ID: 19858762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics.
    Kranzler HR; Burleson JA; Korner P; Del Boca FK; Bohn MJ; Brown J; Liebowitz N
    Am J Psychiatry; 1995 Mar; 152(3):391-7. PubMed ID: 7864265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: outcome after long-term follow-up.
    Peselow ED; Tobia G; Karamians R; Pizano D; IsHak WW
    Psychiatry Res; 2015 Feb; 225(3):680-6. PubMed ID: 25496869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders.
    Riggs PD; Mikulich-Gilbertson SK; Davies RD; Lohman M; Klein C; Stover SK
    Arch Pediatr Adolesc Med; 2007 Nov; 161(11):1026-34. PubMed ID: 17984403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
    Hjalmarsson L; Corcos M; Jeammet P
    Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial.
    Cornelius JR; Salloum IM; Ehler JG; Jarrett PJ; Cornelius MD; Perel JM; Thase ME; Black A
    Arch Gen Psychiatry; 1997 Aug; 54(8):700-5. PubMed ID: 9283504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-term outcome of dysthymia in private practice: clinical features, temperament, and the art of management.
    Haykal RF; Akiskal HS
    J Clin Psychiatry; 1999 Aug; 60(8):508-18. PubMed ID: 10485632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.